Proteomic Analysis Identifies Novel Plasma Biomarkers in Patients With Vestibular Schwannoma.

HYPOTHESIS Patients with sporadic vestibular schwannoma (VS) have unique plasma protein biomarkers that distinguish them from patients without VS. BACKGROUND No reliable molecular biomarker of VS exists. MRI biomarkers offer limited insight into VS pathophysiology. Identification of plasma biomarkers could enhance disease prognostication and guide treatment decisions. METHODS A high-throughput DNA aptamer-based proteomic analysis was performed in plasma samples from 12 individuals, 6 with sporadic, non-irradiated and growing VS and 6 age-matched and sex-matched healthy controls (HCs). Dysregulated proteins were identified using a cutoff value of |log2foldchange|>1 and padj<0.05. Enriched pathways were determined using Ingenuity Pathway and STRING bioinformatic analysis. Biomarker expression was validated in an established human schwannoma cell line and primary VS culture. RESULTS A total of 7310 proteins were profiled. Of 1499 differentially expressed proteins, 152 (10%) were upregulated and 264 (18%) were downregulated in VS. There was an enrichment in cancer proliferation, protein catabolism, and immune cell activation processes. A panel of 40 proteins distinguished VS from HC, accounting for 84% of the variance on principal component analysis. These included members of NF-κB and Wnt signaling pathways (NFKBIA, WNT10A, and WNT16). IGFBP-2 and FCGR3A mRNA expression were significantly elevated in schwannoma cells. Hepcidin (HAMP), a regulator of iron homeostasis that influences tumor growth, was highly expressed in human VS tissue and enriched in primary VS culture secretion. CONCLUSIONS Proteomic analysis of VS patient plasma identified several disease-classifying biomarkers. Hepcidin warrants further investigation into its role in VS progression.

• Publication year

  2025

• Venue

  Otology and Neurotology

• Publication date

  2025-11-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/mao.0000000000004729PMID 41249026
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plasma Matrix Metalloproteinase‐9 Predicts Intraoperative Experience and Extent of Resection in Vestibular Schwannoma Surgery

  2025cited by this paper
• Matrix metalloproteinase 9: An emerging biomarker for classification of adherent vestibular schwannoma

  2024cited by this paper
• Serum IGFBP-1 as a promising diagnostic and prognostic biomarker for colorectal cancer

  2024cited by this paper
• Identification of immune-related candidate biomarkers in plasma of patients with sporadic vestibular schwannoma

  2023cited by this paper
• Identifying Tumor Microenvironment Biomarkers in Adherent and Cystic Vestibular Schwannomas

  2023cited by this paper
• Celastrol suppresses the growth of vestibular schwannoma in mice by promoting the degradation of β-catenin

  2022cited by this paper
• The Effect of Alcohol Consumption in Unresectable Hepatocellular Carcinoma with Transarterial Chemoembolization

  2022cited by this paper
• FCGR3A Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Lower-Grade Glioma

  2022cited by this paper
• Integrative Pan-Cancer Analysis Confirmed that FCGR3A is a Candidate Biomarker Associated With Tumor Immunity

  2022cited by this paper
• Sporadic Vestibular Schwannoma Size and Location Do not Correlate With the Severity of Hearing Loss at Initial Presentation

  2022cited by this paper
• Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models

  2021cited by this paper
• Vestibular Schwannomas.

  2021cited by this paper
• MMP-14 (MT1-MMP) Is a Biomarker of Surgical Outcome and a Potential Mediator of Hearing Loss in Patients With Vestibular Schwannomas

  2020cited by this paper
• Natural History of Growing Sporadic Vestibular Schwannomas: An Argument for Continued Observation Despite Documented Growth in Select Cases

  2020cited by this paper
• Contribution of mTOR and PTEN to Radioresistance in Sporadic and NF2-Associated Vestibular Schwannomas: A Microarray and Pathway Analysis

  2020cited by this paper
• Efficacy and Safety of Bevacizumab for Vestibular Schwannoma in Neurofibromatosis Type 2: A Systematic Review and Meta-analysis of Treatment Outcomes

  2019cited by this paper
• NLRP3 inflammasome activation in human vestibular schwannoma: Implications for tumor-induced hearing loss.

  2019cited by this paper
• Can an Imaging Marker of Consistency Predict Intraoperative Experience and Clinical Outcomes for Vestibular Schwannomas? A Retrospective Review

  2019cited by this paper
• Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.

  2019cited by this paper
• Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models

  2018cited by this paper
• Canonical and Non-Canonical Wnt Signaling in Immune Cells.

  2018cited by this paper
• A Unified Methodological Framework for Vestibular Schwannoma Research.

  2017cited by this paper
• KLK4 silencing inhibits the growth of oral squamous cell carcinoma through Wnt/β‐catenin signaling pathway

  2017cited by this paper
• Current status and recommendations for biomarkers and biobanking in neurofibromatosis

  2016cited by this paper
• Treatment with anti-IL-6 receptor antibody prevented increase in serum hepcidin levels and improved anemia in mice inoculated with IL-6–producing lung carcinoma cells

  2016cited by this paper
• Preclinical validation of anti‐nuclear factor‐kappa B therapy to inhibit human vestibular schwannoma growth

  2015cited by this paper
• Secreted Factors from Human Vestibular Schwannomas Can Cause Cochlear Damage

  2015cited by this paper
• Hepcidin - A novel biomarker with changing trends

  2015cited by this paper
• Roles of the hepcidin–ferroportin axis and iron in cancer

  2014cited by this paper
• Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathway

  2014cited by this paper
• Disordered hepcidin-ferroportin signaling promotes breast cancer growth.

  2014cited by this paper
• Plasma S100β is not a useful biomarker for tumor burden in neurofibromatosis.

  2013cited by this paper
• Sporadic Vestibular Schwannomas Associated With Good Hearing Secrete Higher Levels of Fibroblast Growth Factor 2 Than Those Associated With Poor Hearing Irrespective of Tumor Size

  2013cited by this paper
• Microarray analysis of gene expression in vestibular schwannomas reveals SPP1/MET signaling pathway and androgen receptor deregulation

  2013cited by this paper
• Treatment of Vestibular Schwannoma Cells With ErbB Inhibitors

  2012cited by this paper
• Advances in human proteomics at high scale with the SOMAscan proteomics platform.

  2012cited by this paper
• Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival

  2012cited by this paper
• Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways.

  2011cited by this paper
• ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.

  2010cited by this paper
• Serum S100β

  2003cited by this paper

• No citing papers are available for this paper.